Group 1 - Company Shandong Lukang Pharmaceutical Group Saiter Co., Ltd. received a drug registration certificate for Finasteride tablets from the National Medical Products Administration, indicating approval as a generic drug that meets quality and efficacy consistency evaluation [1] - Finasteride is a synthetic steroid compound that acts as a specific inhibitor of the enzyme 5α-reductase type II, which converts testosterone to dihydrotestosterone (DHT), playing a significant role in benign prostatic hyperplasia (BPH) [1] - The 1mg specification of Finasteride is indicated for the treatment of male pattern baldness, promoting hair growth and preventing further hair loss, while the 5mg specification is used for treating and controlling BPH, improving urinary flow and related symptoms [1] Group 2 - There are currently 46 production approvals for Finasteride tablets in China, with 24 companies holding 29 approvals that have passed or are deemed to have passed the quality and efficacy consistency evaluation [2] - The total sales of Finasteride tablets in hospitals across China for the years 2022, 2023, 2024, and the first half of 2025 are approximately CNY 469 million, CNY 483 million, CNY 490 million, and CNY 343 million respectively [2] - Since the start of research and development, Saiter Company has invested approximately CNY 3.5 million in R&D (unaudited) [2]

Core Viewpoint - The announcement indicates that LuKang Pharmaceutical's subsidiary, Sait Company, has received a drug registration certificate for Finasteride tablets from the National Medical Products Administration, marking it as a generic drug approved under the new registration category 4, which is considered to have passed the consistency evaluation of quality and efficacy [1] Group 1 - LuKang Pharmaceutical's subsidiary, Sait Company, has been granted a drug registration certificate for Finasteride tablets [1] - The approval is categorized as a generic drug under the new registration classification 4 [1] - The drug is recognized as having met the standards for quality and efficacy consistency evaluation [1]

证券代码：600789 证券简称：鲁抗医药 公告编号：2025-058 山东鲁抗医药股份有限公司 上述签署的《募集资金专户存储三方监管协议》内容与上海证券交易所《募 集资金专户存储三方监管协议（范本）》不存在重大差异。 关于公司及全资子公司签署募集资金专户存储监管协议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、募集资金基本情况 经中国证券监督管理委员会《关于同意山东鲁抗医药股份有限公司向特定对 象发行股票注册的批复》（证监许可〔2025〕2158号）核准，山东鲁抗医药股份 有限公司（以下简称"公司"）向特定对象发行人民币普通股（A股）146,520,146 股，发行价格8.19元/股，募集资金总额为人民币1,199,999,995.74元，扣除发 行费用计人民币13,170,857.06元（不含增值税）后，实际募集资金净额为人民 币1,186,829,138.68元。 本次募集资金已于2025年12月15日到账，经和信会计师事务所（特殊普通合 伙）审验，并于2025年12月17日出具了和信验字（2025）第00 ...

山东鲁抗医药股份有限公司 2024 年度向特定对象发行 A 股股票发行情况报告书 证券代码：600789 证券简称：鲁抗医药 山东鲁抗医药股份有限公司 （山东省济宁高新区德源路 88 号） 2024 年度向特定对象发行 A 股股票 发行情况报告书 保荐人（联席主承销商）：中国国际金融股份有限公司 联席主承销商：方正证券承销保荐有限责任公司 二〇二五年十二月 1 山东鲁抗医药股份有限公司 2024 年度向特定对象发行 A 股股票发行情况报告书 发行人全体董事、高级管理人员声明 本公司及全体董事、高级管理人员承诺本发行情况报告书不存在虚假记载、误导性 陈述或重大遗漏，并对其真实性、准确性、完整性承担相应的法律责任。 董事签字： 彭 欣 董 坤 赵 伟 张 晶 张成勇 刘承通 山东鲁抗医药股份有限公司 2 年 月 日 山东鲁抗医药股份有限公司 2024 年度向特定对象发行 A 股股票发行情况报告书 发行人全体董事、高级管理人员声明 本公司及全体董事、高级管理人员承诺本发行情况报告书不存在虚假记载、误导性 冯立亮 山东鲁抗医药股份有限公司 3 陈述或重大遗漏，并对其真实性、准确性、完整性承担相应的法律责任。 独立董事 ...

关于2024 年度向特定对象发行A 股股票发行情况的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 山东鲁抗医药股份有限公司（以下简称"公司"）本次向特定对象发行A股 股票（以下简称"本次发行"）的发行承销总结及相关文件已经上海证券交易所 备案通过，公司将依据相关规定尽快办理本次发行新增股份的登记托管事宜。 证券代码：600789 证券简称：鲁抗医药 公告编号：2025-057 山东鲁抗医药股份有限公司 特此公告。 山东鲁抗医药股份有限公司董事会 2025 年 12 月 23 日 本次发行的具体情况详见公司同日在上海证券交易所网站披露的《山东鲁抗 医药股份有限公司2024年度向特定对象发行A股股票发行情况报告书》及相关发 行文件。 ...

山东昌抗医药股份有限公司 验资报告 和信验字 (2025) 第 000041 号 目 录 页 码 一、验资报告 1-3 二、附件 1、新增注册资本实收情况明细表 2、注册资本及实收资本(股本)变更前后对照表 3、验资事项说明 4、银行询证函 和信会计师事务所(特殊普通合伙) 二〇二五年十二月十七日 山东鲁抗医药股份有限公司 验资报告正文 验 资 报 告 和信验字(2025)第 000041 号 山东鲁抗医药股份有限公司: 我们接受委托,审验了山东鲁抗医药股份有限公司(以下简称"贵公司")截至 2025 年 12月 15 日止新增注册资本及股本情况。按照法律法规以及协议、章程的要求出资, 提供真实、合法、完整的验资资料,保护资产的安全、完整是全体股东及贵公司的责任。 我们的责任是对贵公司新增注册资本及股本情况发表审验意见。我们的审验是依据《中 国注册会计师审计准则第1602号—验资》进行的。在审验过程中,我们结合贵公司的实 际情况,实施了检查等必要的审验程序。 贵公司本次变更前注册资本为人民币 898, 669, 632. 00 元, 股本 898, 669, 632. 00 元。 根据《鲁抗医药 2024年第 ...

北京市通商律师事务所 关于山东鲁抗医药股份有限公司 2024年度向特定对象发行A股股票 发行过程和认购对象合规性的 法律意见书 二〇二五年十二月 中国北京市建国门外大街 1 号国贸写字楼 2 座 12-15 层 100004 12-15th Floor, China World Office 2, No. 1 Jianguomenwai Avenue, Beijing 100004, China 电话 Tel: +86 10 6563 7181 传真 Fax: +86 10 6569 3838 电邮 Email: beijing@tongshang.com 网址 Web: www.tongshang.com 北京市通商律师事务所 关于山东鲁抗医药股份有限公司 2024年度向特定对象发行A股股票发行过程 和认购对象合规性的法律意见书 致：山东鲁抗医药股份有限公司 北京市通商律师事务所（以下简称"本所"）是具有中华人民共和国（为本法 律意见书之目的，不包括香港特别行政区、澳门特别行政区和台湾地区，以下简 称"中国"）法律执业资格的律师事务所。本所接受鲁抗医药的委托，作为山东鲁 抗医药股份有限公司 2024 年度向 ...

中国国际金融股份有限公司、 方正证券承销保荐有限责任公司 关于 山东鲁抗医药股份有限公司 发行过程和认购对象合规性的报告 保荐人（联席主承销商）：中国国际金融股份有限公司 向特定对象发行股票 联席主承销商：方正证券承销保荐有限责任公司 二〇二五年十二月 上海证券交易所： 山东鲁抗医药股份有限公司（以下简称"鲁抗医药""发行人"或"公司"） 2024 年度向特定对象发行 A 股股票（以下简称"本次发行"）已获得中国证券 监督管理委员会（以下简称"中国证监会"）证监许可〔2025〕2158 号文同意 注册批复。 中国国际金融股份有限公司（以下简称"中金公司"或"保荐人（联席主承 销商）"）及方正证券承销保荐有限责任公司（以下简称"方正承销保荐"）（中 金公司、方正承销保荐统称"联席主承销商"）作为鲁抗医药本次发行的联席主 承销商，根据《中华人民共和国公司法》（以下简称"《公司法》"）《中华人 民共和国证券法》（以下简称"《证券法》"）《证券发行与承销管理办法》（以 下简称"《承销管理办法》"）《上市公司证券发行注册管理办法》（以下简称 "《注册管理办法》"）《上海证券交易所上市公司证券发行与承销业务实施细 则》（ ...

Core Viewpoint - Luantang Pharmaceutical is implementing a capital increase plan totaling 1.2 billion yuan to seek new balance amid slowing industry growth, with funds allocated for high-end formulation workshops, biopesticide bases, and new drug research and development [1][2] Group 1: Capital Increase Plan - The company plans to issue up to approximately 270 million A-shares, with a maximum fundraising target of 1.2 billion yuan [1] - The controlling shareholder, Hualu Group, has committed to subscribe for no less than 23.81% of the shares, amounting to about 64.2 million shares, which is seen as a stabilizing factor for market expectations [2] - Approximately 400 million yuan will be allocated to the construction of high-end formulation intelligent manufacturing workshops to enhance production capacity for chronic disease medications [2] Group 2: Financial Performance - In the first three quarters of 2025, the company's net profit attributable to shareholders fell to 141 million yuan, a year-on-year decline of 59.32%, primarily due to the absence of one-time land reserve income [1][7] - The company's revenue for the same period was 4.624 billion yuan, a slight decrease of 0.91% year-on-year, indicating challenges in maintaining revenue growth [7] - Cash flow from operating activities decreased by 24.4% year-on-year to 306 million yuan, suggesting potential issues with cash collection despite reported profits [7] Group 3: Industry Challenges - The pharmaceutical manufacturing industry is transitioning from rapid growth to high-quality development, facing pressure from cost control and research innovation [5] - The core infection business is under pressure from both "antibiotic restrictions" and volume-based procurement, leading to a continuous compression of profit margins in the existing market [5] - In the chronic disease medication sector, intense price competition is evident, with mature generic drugs entering a "micro-profit era" [5] Group 4: Strategic Focus - The company aims to reduce unit production costs through intelligent upgrades in its high-end formulation workshop [6] - Luantang Pharmaceutical is also exploring growth in the non-human medication sector, with veterinary medicine sales projected at 2.476 billion yuan in 2024, accounting for about 40% of total revenue [6] - The company plans to invest 400 million yuan in a biopesticide production base, aiming to leverage synergies across human, veterinary, and agricultural medications [6] Group 5: R&D and Financial Strategy - The company adopts an aggressive capitalization strategy for R&D expenditures, with approximately 154 million yuan allocated to three new drug projects, representing about 77% of the planned R&D investment [3] - A total of 200 million yuan from the fundraising will be used to supplement working capital, which is about 16.7% of the total funds raised [3] - The company faces challenges in managing fixed costs and ensuring that investment projects generate timely returns to avoid further pressure on profits [4][8]

Group 1 - Lu Kang Pharmaceutical plans to increase capital by 109 million yuan to its wholly-owned subsidiary Bio-Pesticide Company and 27 million yuan to Ze Run Company, aiming to expand its pesticide and sales sectors [1] - Hui Green Ecology intends to sell two properties in Ningbo for 12.52 million yuan, expecting a net profit impact of approximately 6.23 million yuan from the transaction [2] - Tianyuan Co., Ltd. plans to invest 185 million yuan in an intelligent upgrade project for its titanium dioxide production facilities [3] Group 2 - Metro Design has received approval from the Shenzhen Stock Exchange for its share issuance to acquire 100% equity of Guangzhou Metro Engineering Consulting Co., Ltd. for 511 million yuan [4] - South Network Energy announced a mid-term profit distribution plan for 2025, proposing a cash dividend of 0.07 yuan per 10 shares [5] - Qibin Group plans to establish two wholly-owned subsidiaries in Shenzhen with a registered capital of 100 million yuan each [6] Group 3 - All New Good received an administrative regulatory decision from the Shenzhen Securities Regulatory Bureau due to issues in financial accounting and information disclosure [7] - Luokai Co., Ltd. announced that its shareholders plan to reduce their holdings by up to 3% of the company's shares [8][9] - Jincheng Pharmaceutical's actual controller received an administrative penalty from the CSRC for stock manipulation, leading to the resignation of the chairman [10] Group 4 - Yicheng New Energy intends to acquire a 7.69% stake in Kaifeng Times for 10 million yuan, enhancing its strategic development [11] - Yujing Co., Ltd. signed a sales contract worth approximately 28.6 million USD with an overseas photovoltaic company [12] - Nuocheng Jianhua's TRK inhibitor, Zoltracitinib, has been approved for market entry in China [13] Group 5 - Nandu Power announced that its controlling shareholder is planning a change in control, leading to a temporary suspension of its stock [14] - Xinxing Casting plans to acquire 100% equity of China Resources Steel for 1.244 billion yuan to focus on special steel development [15] - Xinlitai is planning to issue H-shares and list on the Hong Kong Stock Exchange [16] Group 6 - Blue Fan Medical's subsidiary received approval for a new medical device, the coronary artery scoring balloon dilation catheter [18] - China Iron & Steel plans to establish a joint venture with several companies to provide new energy transportation solutions with a registered capital of 500 million yuan [19] - Jifeng Technology intends to sign a cooperation framework agreement with Dongtai Lianfei for a total transaction amount not exceeding 100 million yuan [20] Group 7 - Zhongwei Electronics announced a change in its actual controller, with stock resuming trading [21] - Weihong Co., Ltd. plans to reduce its holdings by up to 1.15% of the company's shares [22] - Te Fa Information received a criminal judgment related to a fraud case involving the acquisition of Shenzhen Te Fa Dongzhi Technology Co., Ltd. [23] Group 8 - Sunshine Dairy's controlling shareholder's concerted action plans to reduce holdings by up to 3% of the company's shares [24] - Meikailong reported that Taobao Holdings and New Retail Fund collectively reduced their H-shares by 30.616 million shares [25] - Xinjubang plans to issue H-shares and apply for listing on the Hong Kong Stock Exchange [26] Group 9 - Beite Technology's application for issuing A-shares to specific objects has been approved by the Shanghai Stock Exchange [28] - Victory Energy's controlling shareholder is planning a change in control, with stock resuming trading [29] - Jiutian Pharmaceutical signed a patent and technology transfer agreement for a small molecule analgesic drug project, with a total transfer fee not exceeding 400 million yuan [29]